Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.

Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-1259. [Epub ahead of print]

PMID:
31371342
2.

MeV photoelectron spectrometer for ultraintense laser interactions with atoms and molecules.

Luo SY, Grugan PD, Demircioglu Z, Hoos A, Germain Z, McIntyre RA, Shen X, Ji Y, Walker BC.

Rev Sci Instrum. 2019 Jul;90(7):073104. doi: 10.1063/1.5116589.

PMID:
31370482
3.

Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2019 Jun;570(7761):E53. doi: 10.1038/s41586-019-1265-5.

PMID:
31142845
4.

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD.

Blood Cancer J. 2019 Mar 20;9(4):37. doi: 10.1038/s41408-019-0196-6.

5.

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD.

Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.

PMID:
30442502
6.

Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2018 Dec;564(7736):439-443. doi: 10.1038/s41586-018-0705-y. Epub 2018 Nov 7. Erratum in: Nature. 2019 Jun;570(7761):E53.

PMID:
30405246
7.

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.

Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W, Hahn A, Seestaller-Wehr L, Bi M, Vitali NJ, Tsvetkov L, Halsey W, Hughes A, Traini C, Zhou H, Jing J, Lee T, Figueroa DJ, Brett S, Hopson CB, Smothers JF, Hoos A, Srinivasan R.

PLoS One. 2018 Nov 2;13(11):e0206223. doi: 10.1371/journal.pone.0206223. eCollection 2018.

8.

The Partnership for Accelerating Cancer Therapies.

Baker RG, Hoos AX, Adam SJ, Wholley D, Doroshow JH, Lowy DR, Tabak LA, Collins FS.

Cancer J. 2018 May/Jun;24(3):111-114. doi: 10.1097/PPO.0000000000000321. Review.

9.

Leveraging Big Data Towards Functionally-Based, Catchment Scale Restoration Prioritization.

Lovette JP, Duncan JM, Smart LS, Fay JP, Olander LP, Urban DL, Daly N, Blackwell J, Hoos AB, García AM, Band LE.

Environ Manage. 2018 Dec;62(6):1007-1024. doi: 10.1007/s00267-018-1100-z. Epub 2018 Aug 31.

PMID:
30171327
10.

The promise and challenges of immune agonist antibody development in cancer.

Mayes PA, Hance KW, Hoos A.

Nat Rev Drug Discov. 2018 Jul;17(7):509-527. doi: 10.1038/nrd.2018.75. Epub 2018 Jun 15. Review.

PMID:
29904196
11.

What do stakeholders expect from patient engagement: Are these expectations being met?

Boudes M, Robinson P, Bertelsen N, Brooke N, Hoos A, Boutin M, Geissler J, Sargeant I.

Health Expect. 2018 Dec;21(6):1035-1045. doi: 10.1111/hex.12797. Epub 2018 Jun 1.

12.

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, Wolchok JD.

J Clin Oncol. 2018 Mar 20;36(9):850-858. doi: 10.1200/JCO.2017.75.1644. Epub 2018 Jan 17.

PMID:
29341833
13.

Culture and Process Change as a Priority for Patient Engagement in Medicines Development.

Boutin M, Dewulf L, Hoos A, Geissler J, Todaro V, Schneider RF, Garzya V, Garvey A, Robinson P, Saffer T, Krug S, Sargeant I.

Ther Innov Regul Sci. 2017 Jan;51(1):29-38. doi: 10.1177/2168479016659104. Epub 2016 Aug 20.

14.

The European Regulatory Environment of RNA-Based Vaccines.

Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Türeci Ö, Kalinke U.

Methods Mol Biol. 2017;1499:203-222. Review.

PMID:
27987152
15.

Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.

Oye KA, Eichler HG, Hoos A, Mori Y, Mullin TM, Pearson M.

Clin Pharmacol Ther. 2016 Dec;100(6):626-632. doi: 10.1002/cpt.505. Epub 2016 Oct 17.

PMID:
27618128
16.

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P.

Blood. 2016 Nov 24;128(21):2489-2496. Epub 2016 Aug 29. Review.

17.

Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation.

Schulthess D, Baird LG, Trusheim M, Unger TF, Lumpkin M, Hoos A, Garner S, Gavin P, Goldman M, Seigneuret N, Chlebus M, Van Baelen K, Bergstrom R, Hirsch G.

Ther Innov Regul Sci. 2016 May;50(3):347-354. doi: 10.1177/2168479015618697.

PMID:
30227070
18.

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.

Hoos A.

Nat Rev Drug Discov. 2016 Apr;15(4):235-47. doi: 10.1038/nrd.2015.35. Epub 2016 Mar 11.

PMID:
26965203
19.

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.

Hoos A, Wolchok JD, Humphrey RW, Hodi FS.

Clin Cancer Res. 2015 Nov 15;21(22):4989-91. doi: 10.1158/1078-0432.CCR-14-3128.

20.

Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action.

Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, Joos A, Metcalf M, Regnante J, Sargeant I, Schneider RF, Todaro V, Tougas G.

Ther Innov Regul Sci. 2015 Nov;49(6):929-939.

21.

Big opportunities for small molecules in immuno-oncology.

Adams JL, Smothers J, Srinivasan R, Hoos A.

Nat Rev Drug Discov. 2015 Sep;14(9):603-22. doi: 10.1038/nrd4596. Epub 2015 Jul 31. Review.

PMID:
26228631
22.

Guidelines for the automated evaluation of Elispot assays.

Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A.

Nat Protoc. 2015 Jul;10(7):1098-115. doi: 10.1038/nprot.2015.068. Epub 2015 Jun 25.

PMID:
26110715
23.

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.

Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A.

Pigment Cell Melanoma Res. 2015 Sep;28(5):611-2. doi: 10.1111/pcmr.12383. Epub 2015 Jun 23. No abstract available.

24.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A.

Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262. Lancet Oncol. 2016 Jun;17 (6):e223.

PMID:
25840693
25.

From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.

Eichler HG, Baird LG, Barker R, Bloechl-Daum B, Børlum-Kristensen F, Brown J, Chua R, Del Signore S, Dugan U, Ferguson J, Garner S, Goettsch W, Haigh J, Honig P, Hoos A, Huckle P, Kondo T, Le Cam Y, Leufkens H, Lim R, Longson C, Lumpkin M, Maraganore J, O'Rourke B, Oye K, Pezalla E, Pignatti F, Raine J, Rasi G, Salmonson T, Samaha D, Schneeweiss S, Siviero PD, Skinner M, Teagarden JR, Tominaga T, Trusheim MR, Tunis S, Unger TF, Vamvakas S, Hirsch G.

Clin Pharmacol Ther. 2015 Mar;97(3):234-46. doi: 10.1002/cpt.59. Epub 2015 Feb 4.

26.

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A.

Clin Cancer Res. 2015 Apr 1;21(7):1639-51. doi: 10.1158/1078-0432.CCR-14-2339. Epub 2015 Jan 14.

27.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

28.

Metastatic growth progression caused by PSGL-1-mediated recruitment of monocytes to metastatic sites.

Hoos A, Protsyuk D, Borsig L.

Cancer Res. 2014 Feb 1;74(3):695-704. doi: 10.1158/0008-5472.CAN-13-0946. Epub 2013 Dec 9.

29.

The regulatory landscape for actively personalized cancer immunotherapies.

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U.

Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708. No abstract available.

PMID:
24104749
30.

Structured reporting of T cell assay results.

Janetzki S, Hoos A, Melief CJ, Odunsi K, Romero P, Britten CM.

Cancer Immun. 2013 Jul 15;13:13. Print 2013. No abstract available.

31.

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ.

Ann N Y Acad Sci. 2013 Jul;1291:1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17. Review.

32.
33.

Endothelial chemokine receptors as facilitators of tumor cell extravasation?

Hoos A, Wolf MJ, Bauer J, Borsig L, Heikenwalder M.

Oncotarget. 2012 Sep;3(9):919-20.

34.

Evolution of end points for cancer immunotherapy trials.

Hoos A.

Ann Oncol. 2012 Sep;23 Suppl 8:viii47-52. doi: 10.1093/annonc/mds263.

PMID:
22918928
35.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

36.

Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway.

Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M.

Cancer Cell. 2012 Jul 10;22(1):91-105. doi: 10.1016/j.ccr.2012.05.023.

37.

Volatile anesthetics reduce invasion of colorectal cancer cells through down-regulation of matrix metalloproteinase-9.

Müller-Edenborn B, Roth-Zʼgraggen B, Bartnicka K, Borgeat A, Hoos A, Borsig L, Beck-Schimmer B.

Anesthesiology. 2012 Aug;117(2):293-301. doi: 10.1097/ALN.0b013e3182605df1.

38.

The immuno-oncology framework: Enabling a new era of cancer therapy.

Hoos A, Britten C.

Oncoimmunology. 2012 May 1;1(3):334-339.

39.

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.

Revicki DA, van den Eertwegh AJ, Lorigan P, Lebbe C, Linette G, Ottensmeier CH, Safikhani S, Messina M, Hoos A, Wagner S, Kotapati S.

Health Qual Life Outcomes. 2012 Jun 13;10:66. doi: 10.1186/1477-7525-10-66.

40.

A Regional Modeling Framework of Phosphorus Sources and Transport in Streams of the Southeastern United States.

García AM, Hoos AB, Terziotti S.

J Am Water Resour Assoc. 2011 Oct;47(5):991-1010.

41.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

42.

Harmonization of immune biomarker assays for clinical studies.

van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A.

Sci Transl Med. 2011 Nov 9;3(108):108ps44. doi: 10.1126/scitranslmed.3002785. Review.

PMID:
22072636
43.

A methodological framework to enhance the clinical success of cancer immunotherapy.

Hoos A, Britten CM, Huber C, O'Donnell-Tormey J.

Nat Biotechnol. 2011 Oct 13;29(10):867-70. doi: 10.1038/nbt.2000. No abstract available.

PMID:
21997622
44.

Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.

Burke MM, Kluger HM, Golden M, Heller KN, Hoos A, Sznol M.

J Clin Oncol. 2011 Nov 10;29(32):e792-4. doi: 10.1200/JCO.2011.36.9199. Epub 2011 Oct 11. No abstract available.

PMID:
21990407
45.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group.

J Transl Med. 2011 Jul 11;9:108. doi: 10.1186/1479-5876-9-108.

46.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD.

N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.

47.

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM.

Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16.

48.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.

PMID:
21074069
49.

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ.

Cancer Immun. 2010 Oct 20;10:9.

50.

Improved endpoints for cancer immunotherapy trials.

Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J.

J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8. Review.

Supplemental Content

Support Center